Reviewing the Current Treatment Landscape for Patients With HCC

Ahmed Omar Kaseb, MD, associate professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the current treatment landscape for patients with hepatocellular carcinoma (HCC).

All systemic therapy is considered palliative only, Kaseb says. There are not any drugs approved in the neoadjuvant or adjuvant setting for patients with HCC, so many patients who are not surgical candidates suffer from a lack of effective adjuvant therapies to downsize their tumors.